Proteostasis, Astellas deal

Astellas and Proteostasis partnered to use Proteostasis' technologies to discover and develop candidates to modulate the unfolded protein response (UFP). Proteostasis could receive more than $400 million, including an undisclosed upfront payment and equity investment, research funding and development and commercialization milestones. Proteostasis is also eligible for tiered royalties. Astellas has the right to begin two additional projects under the same terms, which would bring the total value of the deal to $1.2 billion. ...